TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Achievement of Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Women Not Attending Follow-up Screening Appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retentive strength of adhesives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of the treatment program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum tolerated dose (MTD) or recommended clinical dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and degree of Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: urinary morphine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: times or days of heroin use during the previous week
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Alopecia Areata Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Eating Attitudes Test (ChEAT) Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Systemic Lupus Erythematosus primary outcome
Endpoint domain: Physiological/clinical
Primary endpoint: Sjogren syndrome primary outcome
Endpoint domain: Physiological/clinical
Primary endpoint: Inflammatory Myopathy primary outcome
Endpoint domain: Physiological/clinical
Primary endpoint: Systemic Sclerosis primary outcome
Endpoint domain: Physiological/clinical
Primary endpoint: Behçet's Disease primary outcome
Endpoint domain: Physiological/clinical
Primary endpoint: ANCA associated Vasculitis primary outcome
Endpoint domain: Physiological/clinical
Primary endpoint: Heart Failure Incidence
Endpoint domain: Mortality/survival
Primary endpoint: Liver fibrosis score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major bleeding (type 3b or 5 BARC bleeding)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with IBS symptoms with evidence of epithelial barrier dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Success of the implant borne prostheses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants who Experience a Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants who Experience an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants who Experience Clinically Significant Changes in Clinical Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: validated clinical result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: GMT level against HPV 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detrusor Muscle Representation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in composite gene expression score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of Mediterranean diet on vaginitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resisted sprinting speeds at 10-30 m
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of direction speed (COD) testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Squat jumps (SJ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal Jump (HJ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from Baseline Body Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from Baseline Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from Baseline Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Individual Self-Esteem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Baseline muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Area Hair Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characteristics of neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hepatopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: stoma compliance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Retinal response amplitude in voltage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of venipunctures performed per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Persistent MRD-negative rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with TEAEs Leading to Treatment Interruptions, Dose Reductions and Permanent Discontinuations
Endpoint domain: Adverse events/effects
Primary endpoint: Course interest scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Difference in physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnostic performance of methods for CMV infection diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Personality belief scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cyberbullying behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mutational burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in the time in notes per note
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of upper mediastinal lymph nodes dissected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Parent's degree of agreement/disagreement with pediatric procedural analgosedation practices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective sleep indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical sleep-related scales
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Volume of bone reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Matrix bonding to the bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Frailty score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Frailty status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the isometric force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg length estimation differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the iAUC for total amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in the iAUC for glucagon-like peptide-1 (GLP-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in the iAUC for Cholecystokinin (CCK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in the iAUC for peptide YY (PYY)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in the iAUC for Gastric inhibitory polypeptide (GIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Safety of revascularization
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration of lidocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular and Perfusion Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Performance of cyst excision surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complete clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intracranial objective response rate (CNS ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Telemedicine Usability Questionnaire (TUQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 24 h Urine sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Water excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy (percentage of correct responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: reaction time (in ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in consideration of future consequences
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of defense mechanisms level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of mindful awareness level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in daily living activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Critical Closing Pressure (CrCP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percent of participants able to complete treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Sensitivity of ausculto™
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of ausculto™
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The Roland Morris Disability Questionnaire (RMDQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Insomnia Severity Index (ISI) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Clinically significant portal hypertension (PH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of participants reporting Unsolicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with any clinically significant hematological and biochemical laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants reporting medically attended adverse events (MAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Teacher-rated problem behavior in the classroom
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of participants with a reaction to the vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment-related allergic reaction adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: CollaboRATE survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Jefferson Scale Patient Perceptions of Physician Empathy (JSPPPE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Regional Cerebral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cerebrovascular outcomes
Primary endpoint: Contemplation Ladder score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-reported OTC NSAID use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients with ongoing urinary retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in MVPA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Transplant free survival
Endpoint domain: Mortality/survival
Primary endpoint: Physical activity practice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adults adherence to the Mediterranean diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child adherence to the Mediterranean diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major congenital malfunctions
Endpoint domain: Mortality/survival
Primary endpoint: Area under the concentration-time curve from time zero to time infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to the time of the last quantifiable (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Minutes Walking Distance (6 DWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance traveled in ISWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 seconds sit to stand test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: evaluation of cervical region biomechanic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fat tissue distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sterile radiolucent bead location distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic capacity of 'globular uterus' for adenomyosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Compliance of the Exercise Prescription
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Gastrointestinal symptom rating scale (GSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of children on directly observed therapy (DOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatment-emergent adverse events (TEAEs) and treatment related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of TEAEs and treatment related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with abnormal clinically significant laboratory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric prehensile hand strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of baseline heterogeneity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in post voided residual
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in International Prostate Symptoms Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Corneal imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients alive without evidence of ARDS
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients assigned to each category of a six-category ordinal scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Anxiety and Depression Scale (RCADS)-25
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neuro-QoL Fatigue Short Form v1
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Five Times Sit-To-Stand Test (5XSST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constipation severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Freedom from device or procedure related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmation of functional LAA closure as defined by residual peri-device flow ≤ 5mm per TEE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of environmental enteropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Discharge opioids consumed in 30 days after discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MMS Adherence (amount)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: MMS Adherence (frequency)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Attendance/Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Functional Rating Index (I-FRI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: N2 peak amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Motor Activity Log-Amount of Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fugl-Meyer Upper-Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Upper-Extremity Activity Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mid-thigh muscle cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total Body Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent change from Baseline in Psoriasis Area Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving treatment success by the 5-point static Investigator's Global Assessment modified 2011 version (sIGA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of decline of percent predicted diffusing capacity for carbon monoxide (ppDLCOadj)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in Blood Routine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in Urine Routine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in the Health Assessment Questionnaire Disability Index (HAQ-DI) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in the Disease Activity Score (DAS 28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in the Brief Fatigue Inventory-Taiwan (BFI-T)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of subjects consented per month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Deoxyribonucleic acid (DNA) quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deoxyribonucleic acid (DNA) quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in oxygen pulsed saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Visualization of Both Column Fixation Corridor (BCFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Placement of Both Column Screws (BCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in average ankle dorsiflexion (degrees)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Complete Pathological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in clinical and radiological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hoehn and Yahr Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hand mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-TST reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive effort
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Decision accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trust change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life and accessibility to healthcare and cure for MEN1 patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overactive Bladder Questionnaire short-form (OAB-q SF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Amount of menstrual blood lost (mL/cycle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Immunoglobulin G (IgG) antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility as assessed by a purposefully designed feasibility questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status